title: Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration.
abstract: OBJECTIVE
  To study the ability to appreciate qualitative features that indicate disease activity in patients with neovascular age-related macular degeneration (AMD) and to analyze the differences in automated retinal thickness measurement, using 1 time domain optical coherence tomography (TD-OCT) and 2 different spectral-domain OCT (SD-OCT) machines.
  
  
  METHODS
  Thirty-three consecutive naïve patients with neovascular AMD underwent Stratus TD-OCT, Cirrus SD-OCT and Spectralis SD-OCT, at baseline, 1 h, 1 day, 1 week and 1 month after intravitreal ranibizumab injection.
  
  
  RESULTS
  As regards the ability to detect retinal cysts, subretinal fluid and pigment epithelium detachment, at each follow-up visit, there was a significant correlation among all 3 OCT devices (p < 0.05), even though Cirrus SD-OCT and Spectralis SD-OCT showed the highest level of intermachine agreement. At each follow-up visit, automated retinal thickness measurements showed a greater mean central macular thickness (CMT) for both Spectralis SD-OCT and Cirrus SD-OCT, compared with Stratus TD-OCT. However, the mean paired differences in CMT among the 3 OCT devices were not statistically significant (p > 0.05). Overall, Cirrus SD-CT showed fewer segmentation errors, compared with both Spectralis SD-OCT and Stratus TD-OCT.
  
  
  CONCLUSIONS
  SD-OCT showed a greater ability to evaluate qualitative features indicating disease activity and fewer errors in automated segmentation. However, differences in CMT changes were similar between TD-OCT and SD-OCT systems during follow-up.
authors.affiliation: Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, University Paris XII, Créteil, France. giuseppe.querques@hotmail.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Querques
authors.forename: Raimondo
authors.initials: R
authors.lastname: Forte
authors.forename: Elya
authors.initials: E
authors.lastname: Berboucha
authors.forename: Domenico
authors.initials: D
authors.lastname: Martinelli
authors.forename: Gabriel
authors.initials: G
authors.lastname: Coscas
authors.forename: Gisele
authors.initials: G
authors.lastname: Soubrane
authors.forename: Eric H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003560:Cysts / Q000175:diagnosis; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D010857:Pigment Epithelium of Eye; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000175:diagnosis; D041623:Tomography, Optical Coherence / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069579:Ranibizumab